Divesiran: First-in-class investigational siRNA therapy for polycythemia vera (PV)

Divesiran is a first-in-class siRNA therapy in clinical development for PV, with best-in-class potential. PV is a chronic myeloproliferative neoplasm ─ a type of rare blood cancer ─ characterized by the excessive production of red blood cells, which can be associated with a higher rate of death from cardiovascular and thrombotic events.

Discovered through the Silence mRNAi GOLD™ platform, divesiran is designed to selectively silence TMPRSS6, a gene involved in regulating hepcidin, the body’s key regulator of iron metabolism. By increasing hepcidin levels, divesiran aims to limit iron availability for red blood cell production, helping to control hematocrit levels and potentially reducing the need for frequent therapeutic phlebotomies.

Results from the Phase 2 SANRECO study of divesiran in phlebotomy-dependent PV patients support a potentially best-in-class profile with once-every-three-month dosing. A Phase 3 study is planned for 2027.

 

Learn More About the SANRECO Study

Learn More About PV